Harold Bernstein Sells 5,106 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,106 shares of Maze Therapeutics stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $135,155.82. Following the completion of the transaction, the chief marketing officer directly owned 14,894 shares in the company, valued at $394,244.18. This represents a 25.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $26.21 on Friday. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65. The firm has a fifty day moving average of $28.69 and a 200-day moving average of $31.17. The firm has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). As a group, analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its stake in shares of Maze Therapeutics by 54,096.5% during the second quarter. California State Teachers Retirement System now owns 777,720 shares of the company’s stock valued at $23,207,000 after acquiring an additional 776,285 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after acquiring an additional 465,641 shares during the last quarter. AXQ Capital LP lifted its stake in shares of Maze Therapeutics by 114.1% in the second quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after acquiring an additional 8,098 shares in the last quarter. Braidwell LP purchased a new position in Maze Therapeutics in the second quarter valued at about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Maze Therapeutics by 4,054.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after purchasing an additional 17,312 shares during the last quarter.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Wall Street Analyst Weigh In

MAZE has been the subject of several analyst reports. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, BTIG Research restated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.